Showing 6481-6490 of 8695 results for "".
- Castle Biosciences' DecisionDx-Melanoma Test Improved AJCC-Based Risk Prediction for Melanoma Recurrence, Metastasishttps://practicaldermatology.com/news/castle-biosciences-decisiondx-melanoma-test-improved-ajcc-based-risk-prediction-for-melanoma-recurrence-metastasis/2457664/Castle Biosciences, Inc’s. DecisionDx®-Melanoma test improved risk prediction beyond that using American Joint Committee on Cancer (AJCC) based staging, according to a new study presented at the DERM2018 NP/PA CME Conference held in Las Veg
- FDA Cracks Down on Energy-Based Vaginal Rejuvenationhttps://practicaldermatology.com/news/fda-cracks-down-on-vaginal-rejuvenation/2457667/The FDA is cracking down on the use energy-based devices to perform vaginal 'rejuvenation.' The use of such devices to perform vaginal "rejuvenation," cosmetic vaginal procedures, or non-surgical vaginal procedures to treat symptoms related to menopause, urinary incontin
- Experimental Drug May Reverse Hair Loss, Hair Whitening and Skin Inflammationhttps://practicaldermatology.com/news/experimental-drug-may-reverse-hair-loss-hair-whitening-and-skin-inflammation/2457669/An experimental drug can successfully reverse hair loss, hair whitening and skin inflammation linked by previous studies to human diets heavy in fat and cholesterol, according to a new Johns Hopkins study in mice. The investigators say the compound halts the production of glycosphingolipi
- SENTÉ Launches Dermal Contour Pressed Serumhttps://practicaldermatology.com/news/sent-launches-dermal-contour-pressed-serum/2457670/Senté's Dermal Contour Pressed Serum with 3 glycosaminoglycan analogs to help tighten skin for a more youthful contour is now availalbe. Patented Heparan Sulfate Analog (HSA) combined with Dermatan Sulfate Analog (DSA) and Chondroitin, Sulfate Analog (CSA), the company's proprietar
- Catch a Sneak Peek of Ground Up Season 2 at Summer AADhttps://practicaldermatology.com/news/get-a-sneak-peek-of-ground-up-season-2-at-summer-aad/2457671/The publishers of Practical Dermatology® and Modern Aesthetics® magazines are offering a sneak peek of the coming new season of the acclaimed video series, Ground Up, at Summer AAD in Chicago. Ground Up Season 1 took viewers
- Survey: Most Women Think Their Hands Make Them Look Oldhttps://practicaldermatology.com/news/survey-most-women-think-their-hands-make-them-look-old/2457674/Just shy of 80 percent of women ages 40 and older wish they could change the way their hands look, according to Nestlé Skin Health’s 'Face Your Hands' survey. Additionally, 60 percent reported they have actually taken step
- Link Between Diet and Skin Disease Takes Center Stage at Summer AADhttps://practicaldermatology.com/news/link-between-diet-and-skin-disease-takes-center-stage-at-summer-aad/2457672/Dermatologists must help patients determine if there are any foods that may cause their skin condition to flare and provide evidence-based recommendations about next steps. “People looking to improve their skin health may think that changing their diet is the answer, but a derm
- Skin Cancer Risk Varies Based on Organ Transplant Patients' Skin Tonehttps://practicaldermatology.com/news/skin-cancer-risk-varies-based-on-organ-transplant-patients-skin-tone/2457673/Dermatologists must know how to evaluate organ transplant patients’ unique risk factors for skin cancer and counsel these patients accordingly. “Individuals who receive organ transplants need to take immunosuppressive medications for the rest of their lives, and this makes it
- AAD: Research Shows Free Skin Cancer Screenings Can Help Save Liveshttps://practicaldermatology.com/news/aad-research-shows-free-skin-cancer-screenings-can-help-save-lives/2457675/Data indicates that American Academy of Dermatology’s (AAD's) SPOTme program serves an important need. While skin cancer can be deadly, it is also highly treatable when detected early. In fact, melanoma, the deadliest form of skin cancer, has a five-year survival rate of 95 percen
- Almirall: Phase 3 Studies of KX2-391 for AK Meet Primary Endpointshttps://practicaldermatology.com/news/almirall-phase-3-studies-of-kx2-391-for-ak-meet-primary-endpoints/2457676/Both Phase 3 studies of KX2-391met the primary endpoint of complete clearance of actinic keratosis (AK) lesions at day 57 within the face or scalp treatment areas, Almirall, SA reports. Each study achieved statistical significance on this endpoint. The double-blind, randomized, vehi